STAT: Gilead’s short-term win threatens the future of pharmaceutical public-private partnerships
On Dec. 19, 2024, we joined other professors of law, medicine, and public health to file an amicus brief in support of the U.S. government in the government’s landmark patent lawsuit against leading HIV drugmaker Gilead Sciences Inc.
On Jan. 15, 2025, the U.S. government and Gilead announced a settlement of the suit that — at least based on what’s been made public — allows Gilead to expropriate publicly funded, publicly owned patents essentially without recourse.